Corporate Action-Intimation of Buy back
Application for buyback of securities in open market09-11-2018
09-11-2018
Natco Pharma looks to improve domestic revenues with more product launches
Domestic market has contributed a third of Natco Pharma's revenues of Rs 22 billion in 2017-18, though slipped in sales for the first time08-11-2018
Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the Q2 FY1908-11-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO records INR 583.40 Crores consolidated revenue and INR 181.50 Crore of profit, after tax, for the Second Quarter, FY2018-1905-11-2018
Natco Pharma Q2 PAT jumps over two-fold to Rs 181.6 cr
Natco Pharma on Monday reported over two-fold increase in consolidated profit after tax at Rs 181.6 crore for the second quarter ended September 30,05-11-2018
Board approves Buyback of equity shares
Natco Pharma Ltd has informed BSE about Outcome of Board Meeting held on November 05, 2018.05-11-2018
Un-Audited Financial Results For The Quarter And Half Year Ended 30Th September, 2018
Un-audited Financial Results for the quarter and half year ended 30th September, 201805-11-2018
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earning call for the Quarter and half year ended September 30, 201805-11-2018
Closure of Trading Window
Please further note that pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 TRADING WINDOW for dealing in the securities of the Company will be closed from 11.15 a.m on 29th October, 2018 to 7th November, 2018 (both days inclusive). Trading window will be opened from 8th November, 201829-10-2018